Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals
Central Nervous System Diseases
Reverse Transcriptase Inhibitors
In a large controlled trial, efavirenz use was associated with neurologic symptoms distinct from depression and anxiety that began early in therapy but resolved by week 4. Improvement in neuropsychological performance was comparable in patients who were receiving efavirenz and those who were not.